GSK3862995 / GSK - LARVOL DELTA

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis (clinicaltrials.gov) - P2 | N=400 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P2 trial • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Jun 2026 ➔ Mar 2027 | Trial primary completion date: Jun 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases